| Title |
Avanafil for treatment of erectile dysfunction: review of its potential
|
|---|---|
| Published in |
Vascular Health and Risk Management, August 2012
|
| DOI | 10.2147/vhrm.s26712 |
| Pubmed ID | |
| Authors |
Ryan M Burke, Jeffery D Evans |
| Abstract |
Avanafil is a medication that was recently approved by the US Food and Drug Administration for the management of erectile dysfunction. Avanafil is a new phosphodiesterase type 5 inhibitor similar to sildenafil and tadalafil. Avanafil was studied in over 1300 patients during clinical trials, including patients with diabetes mellitus and those who had undergone radical prostatectomy, and was found to be more effective than placebo in all men who were randomized to the drug. The medication was studied with on-demand dosing that may occur after food and/or alcohol. Avanafil is dosed as 50 mg, 100 mg, or 200 mg tablets. Avanafil may differentiate itself from the other phosphodiesterase type 5 inhibitors with its quicker onset and higher specificity for phosphodiesterase type 5 versus other phosphodiesterase subtypes, but may lead to complications of therapy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 74 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 74 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 10 | 14% |
| Researcher | 7 | 9% |
| Student > Doctoral Student | 7 | 9% |
| Other | 6 | 8% |
| Professor > Associate Professor | 5 | 7% |
| Other | 14 | 19% |
| Unknown | 25 | 34% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 19% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Chemistry | 2 | 3% |
| Social Sciences | 2 | 3% |
| Other | 4 | 5% |
| Unknown | 28 | 38% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 April 2023.
All research outputs
#2,655,915
of 25,374,917 outputs
Outputs from Vascular Health and Risk Management
#77
of 804 outputs
Outputs of similar age
#17,002
of 179,162 outputs
Outputs of similar age from Vascular Health and Risk Management
#2
of 14 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 804 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.3. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 179,162 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 90% of its contemporaries.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.